Nundina › Discover calendars › FDA New Drug Approvals calendar › FDA approves Mimrylo (rusfertide acetate)FDA approves Mimrylo (rusfertide acetate)28 August 2026The FDA approved Mimrylo (rusfertide acetate), a drug from Takeda Pharms AM. Form: Powder, Subcutaneous. Granted priority review, reserved for treatments that would be a significant improvement over what exists. Application NDA220605.FDA New Drug Approvals calendarMore from this calendar

19 October 2026 - FDA approves Calrezdy (calcuim chloride)

19 October 2026 - FDA approves Cienby (sodium ctirate)

16 October 2026 - FDA approves Yulzety (rivaroxaban)

16 October 2026 - FDA approves Brytly (brytly (apraclonidine))

15 October 2026 - FDA approves Evoxac (cevimeline hydrochloride)